Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects

Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, efavirenz, and abacavir in human immunodeficiency virus-infected subjects who received indinavir at 1,000 mg every 8 h (q8h) and efavirenz at 600 mg q24h or indinavir at 1,200 mg and efavirenz at 300 mg q12...

Description complète

Détails bibliographiques

Publié dans:	Antimicrob Agents Chemother
Auteurs principaux:	DiCenzo, Robert, Forrest, Alan, Squires, Kathleen E., Hammer, Scott M., Fischl, Margaret A., Wu, Hulin, Cha, Raymond, Morse, Gene D.
Format:	Artigo
Langue:	Inglês
Publié:	American Society for Microbiology (ASM) 2003
Sujets:	Antiviral Agents
Accès en ligne:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC155818/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12760869/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.6.1929-1935.2003
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!